TABLE 6.
Respiratory therapy and medications at time of enrolment for the entire cohort and by primary World Symposium on Pulmonary Hypertension (WSPH) group
| Overall (n=1475) | WSPH group# | p-value | |||||
|---|---|---|---|---|---|---|---|
|
|
|||||||
| Group 1 (n=663) | Group 2 (n=54) | Group 3 (n=720) | Group 4 (n=8) | Group 5 (n=30) | |||
|
| |||||||
| Median (IQR) time since PH diagnosis, years | 1.3 (0.2–4.8) | 1.6 (0.1–5.6) | 0.8 (0–4.1) | 1.2 (0.3–4.0) | 0.2 (0–3.8) | 1.1 (0.2–4.3) | 0.45 |
| Any respiratory treatment ¶ | 945 (64) | 363 (55) | 22 (41) | 537 (75) | 5 (63) | 18 (60) | <0.001 |
| On any PH medication | 932 (63) | 515 (78) | 34 (63) | 361 (50) | 4 (50) | 18 (60) | <0.001 |
| CCB | 71 (5) | 46 (7) | 1 (2) | 19 (3) | 0 (0) | 5 (17) | <0.001 |
| ERA | 313 (21) | 227 (34) | 5 (9) | 74 (10) | 2 (25) | 5 (17) | <0.001 |
| PDE5 inhibitor | 819 (56) | 447 (68) | 32 (59) | 323 (45) | 2 (25) | 15 (50) | <0.001 |
| Prostacyclin | 232 (16) | 180 (27) | 5 (9) | 46 (6) | 0 (0) | 1 (3) | <0.001 |
| Inhaled nitric oxide | 60 (4) | 30 (5) | 3 (6) | 25 (4) | 2 (25) | 0 (0) | 0.31 |
| Selexipag | 1 (0.1) | 1 (0.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.30 |
| PH medications | <0.001 | ||||||
| Monotherapy | 526 (36) | 226 (34) | 23 (43) | 263 (37) | 3 (38) | 11 (37) | |
| Combination | 406 (28) | 289 (44) | 11 (20) | 98 (14) | 1 (14) | 7 (23) | |
| None | 542 (37) | 147 (22) | 20 (37) | 359 (50) | 4 (50) | 12 (40) | |
| Monotherapy | 526 | 226 | 23 | 263 | 3 | 11 | 0.005 |
| CCB | 29 (6) | 16 (7) | 1 (4) | 10 (4) | 0 (0) | 2 (18) | |
| ERA | 32 (6) | 17 (8) | 0 (0) | 13 (5) | 1 (33) | 1 (9) | |
| PDE5 inhibitor | 425 (81) | 167 (74) | 21 (91) | 228 (87) | 1 (33) | 8 (73) | |
| Prostacyclin | 18 (3) | 13 (6) | 1 (4) | 4 (2) | 0 (0) | 0 (0) | |
| Inhaled nitric oxide | 22 (4) | 13 (6) | 0 (0) | 8 (3) | 1 (33) | 0 (0) | |
| Selexipag | 0 | 0 | |||||
| On any PH-associated medication | 805 (55) | 409 (62) | 40 (74) | 337 (47) | 4 (50) | 15 (50) | <0.001 |
| PGE1 | 13 (1) | 2 (0.3) | 0 (0) | 11 (2) | 0 (0) | 0 (0) | 0.018 |
| Dopamine | 34 (2) | 15 (2) | 1 (2) | 18 (3) | 0 (0) | 0 (0) | 0.78 |
| Milrinone | 32 (2) | 13 (2) | 1 (2) | 18 (3) | 0 (0) | 0 (0) | 0.50 |
| Aspirin | 144 (10) | 103 (16) | 15 (28) | 24 (3) | 0 (0) | 2 (7) | <0.001 |
| Coumadin | 78 (5) | 63 (10) | 5 (9) | 5 (0.7) | 3 (38) | 2 (7) | <0.001 |
| Digoxin | 91 (6) | 59 (9) | 9 (17) | 21 (3) | 0 (0) | 2 (7) | <0.001 |
| Diuretics | 565 (38) | 261 (39) | 34 (63) | 259 (36) | 1 (13) | 10 (33) | 0.19 |
| Iron supplement | 155 (11) | 55 (8) | 4 (7) | 94 (13) | 0 (0) | 2 (7) | 0.003 |
| Plavix | 4 (0.3) | 4 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.037 |
| Thyroid replacement | 65 (4) | 35 (5) | 3 (6) | 24 (3) | 0 (0) | 3 (10) | 0.07 |
Data are presented as n (%), unless otherwise stated; percentages represent the percentage of patients prescribed the listed treatment within each WSPH group. IQR: interquartile range; PH: pulmonary hypertension; CCB: calcium channel blocker; ERA: endothelin receptor agonist; PDE5: phosphodiesterase type 5; PGE1: PGE1: prostaglandin E1.
medications data were missing for n=1 patient in Group 1, and respiratory therapy data were missing for n=1 patient in Group 1 and n=1 patient in Group 3;
respiratory treatments are defined as supplemental oxygen, airway medications and noninvasive or invasive respiratory support. The p-value reflects the comparison of the percentage of patients on each medication or tests equality of the distributions of the medication types for the Group 1 versus Group 3 cohorts (p<0.05 is significant).